John Brottem's departure as General Counsel of Outset Medical, Inc. was reported, effective September 11, 2026; the filing names no successor. As of November 6, 2026, Outset Medical, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 29, 2026 to August 28, 2026, naming 2 departures (Form 8-K, August 28, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Outset Medical, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Outset Medical, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-29 to 2026-08-28. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Outset Medical, Inc. files it.
Also on the record for Outset Medical, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 6, 2026 | Stake report, Schedule 13G/A, by BML Investment Partners, L.P. | 14.7% of the class | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G, by AQR Capital Management, LLC | 5.39% of the class | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G/A, by BANK OF AMERICA CORP /DE/ | 3.5% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 2% of the class | 5%+ stakes | Source |
| May 18, 2026 | Stake report, Schedule 13G/A, by BML Investment Partners, L.P. | 13.6% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Alyeska Investment Group, L.P. | — | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Woodline Partners LP | 1.6% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G/A, by BML Investment Partners, L.P. | 11.8% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Durable Capital Partners LP | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by PFM Health Sciences, LP | 2.9% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by BML Investment Partners, L.P. | 10.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Outset Medical, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Outset Medical, Inc. and the records around it.
Outset Medical, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- PFM Health Sciences, LP also filed stake reports on 2 other companies: PMV Pharmaceuticals, Inc. (Aug 2025), Werewolf Therapeutics, Inc. (Aug 2025)
- Durable Capital Partners LP also filed stake reports on 13 other companies: Shift4 Payments, Inc. (Aug 2026), Goosehead Insurance, Inc. (Aug 2026), Colliers International Group Inc. (May 2026)
- BML Investment Partners, L.P. also filed stake reports on 15 other companies: LENZ Therapeutics, Inc. (Nov 2026), Seer, Inc. (Nov 2026), Connect Biopharma Holdings Ltd (Oct 2026)
Watch Outset Medical, Inc.
Get an email when Outset Medical, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Outset Medical, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Outset Medical, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Outset Medical, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 20 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-28 | Out | General Counsel | 2026-09-11 | 8-K, 2026-08-28 | |
| 2026-05-29 | Out | Executive Vice President | 2026-06-05 | 8-K, 2026-05-29 |
Who leads Outset Medical, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- General Counsel: John Brottem, departure reported, effective 2026-09-11 (filed 2026-08-28). No successor is named in these filings.
- Executive Vice President: Marc Nash, departure reported, effective 2026-06-05 (filed 2026-05-29). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Outset Medical, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the General Counsel at Outset Medical, Inc., with the record behind each one.
Find candidates like General Counsel at Outset Medical, Inc.Every change, in the filing's words
Departing: John Brottem, General Counsel, effective 2026-09-11
On August 27, 2026, John Brottem informed Outset Medical, Inc. (the "Company") of his decision to depart from the Company and his role as General Counsel, effective September 11, 2026, to pursue other professional opportunities.
- Mr. Brottem's departure is not due to any dispute or disagreement with the Company or its management.
Departing: Marc Nash, Executive Vice President, effective 2026-06-05
On May 26, 2026, Marc Nash informed Outset Medical, Inc. (the "Company") of his decision to depart from the Company and his role as Executive Vice President, R&D, Operations and Service, effective June 5, 2026, to pursue other professional opportunities.
- Mr. Nash's departure is not due to any dispute or disagreement with the Company or its management.
Tools for this story
Each opens in a new tab, filled in for Outset Medical, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.